Suppliers / Rovi Pharma Industrial Services

Rovi Pharma Industrial Services

Spain 784 employees Updated 9 July 2026

Rovi Pharma Industrial Services is a finished-dose manufacturer based in Spain. It appears in 11 regulatory filings across 4 regulators, without an active US DMF or CEP on file. Its filings concentrate with ARCSA (EC), NCELS (KZ) and INVIMA (CO). Its GMP standing is certified by ANVISA (Brazil), MFDS (Korea) and US FDA, among 5 authorities. Its most recent recorded inspection, by US FDA, closed on 10 June 2025 as NAI.

0
active US DMFs
0
valid CEPs
7
registered plants 3 with an FDA FEI number
11
filings across 4 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
3 of 3 confirmed
Inspections
8 of 8 confirmed
EU GMP
1 of 1 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026. EudraGMDP (MIA + third-country GMP certs), read 4 May 2026.

Inspection history

  • 10 June 2025 NAI US FDA
  • 31 January 2025 VAI US FDA
  • 14 March 2024 VAI US FDA
  • 17 January 2024 VAI US FDA
  • 3 June 2021 VAI US FDA
  • 5 April 2021 VAI US FDA
  • 25 September 2018 NAI US FDA
  • 14 September 2018 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Madrid, United Arab Emirates Not on file
ALCALÁ DE HENARES, Spain Not on file
Spain, Spain 3016688535
Madrid, Spain Not on file
Spain, Spain 3007512884
Madrid, Spain Not on file

1 further sites are on record.

Filings and GMP by regulator

Regulator Filings GMP certificates
ARCSA (EC) 5 None
NCELS (KZ) 3 None
INVIMA (CO) 2 None
MINSA (CR) 1 None
ANVISA (Brazil) None 11
MFDS (Korea) None 4
US FDA None 3
AEMPS (ES) None 3
EMA None 1

Comparing suppliers?

Choose your molecules and target markets. Rovi Pharma Industrial Services comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was NAI, on 10 June 2025.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates